Ennov recognized by Gartner in the Hype Cycles for Life Sciences

September 7, 2016

Ennov a Recognized Vendor in 4 Different Technology Areas

Ennov today announced it has been listed four times by Gartner as a vendor in the 2016 “Hype Cycle for Life Science Research and Development”*, and twice in the 2016 “Hype Cycle for Life Sciences”**.
This recognizes the relevance of Ennov’s products in the EDMS, RIM and Pharmacovigilance categories. The reports are available on the Gartner website at:

Gartner’s Hype Cycle for Life Science
Gartner’s Hype Cycle for Life Science Research and Development

According to Gartner, Ennov is a sample vendor for the four following product categories in Life Science:

  • SaaS-Regulated EDMS (pages 23/24)
  • Global Regulatory Information Management (pages 67/68)
  • Global Pharmacovigilance/Safety/AERS (pages 71 to 73)
  • eTMF (electronic trial master file) (pages 60 to 63)

SaaS-Regulated EDMS and eTMF are considered in the study as high benefit technologies, with 2 to 5 years to mainstream adoption in the Life Sciences sector.
Global Regulatory Information Management is considered in the study as a moderate benefit technology, with 2 to 5 years to mainstream adoption in the Life Sciences sector.
Global Pharmacovigilance/Safety/AERS is considered in the study as a moderate benefit technology, with less than 2 years to mainstream adoption in the Life Sciences sector.
About the Hype Cycle for Life Sciences

The Gartner Hype Cycle studies assess the impact of emerging technologies for a specific market. Relevant technologies are positioned through their:

  • Development stage (Innovation Trigger, Peak of Inflated Expectations, Trough of Disillusionment and Plateau of Productivity)
  • Number of years to mainstream adoption
  • Average benefit for the industry (low, moderate, high, transformational)
  • Market penetration
  • Maturity level

A limited number of sample vendors are mentioned in each technology area.

About Gartner

Gartner does not endorse any vendor, product or service depicted in its research publications, and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner research publications consist of the opinions of Gartner’s research organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this research, including any warranties of merchantability or fitness for a particular purpose.

About Ennov

Ennov provides a suite of software that enable Life Science companies to manage their regulated contents in an efficient way. This suite comprises software for the management of Quality, Pharmacovigilance, Regulatory and Clinical contents and processes.
Ennov has more than 150 Life Science customers in more than 10 countries, and more than 100,000 users. Pharmaceutical & biotech, medical device, cosmetics, specialty chemical and CRO companies trust Ennov’s solutions for the improvement of their regulated content management.
Prominent Ennov customers include Caligor RX, Ceva, Horiba, Merck, Septodont, Virbac, Innothera, Air Liquide, Alchem, BASF, Charles River, GSK, Linde, Novartis, Supersonic Imagine, Transgene, Debiopharm, Unither. Please visit us at

* Hype Cycle for Life Science Research and Development, 2016
Published: 19 July 2016
Analyst(s): Michael Shanler

** Hype Cycle for Life Sciences, 2016
Published: 19 July 2016
Analyst(s): Michael Shanler, Stephen Davies

Contact

Olivier Pâris, Ennov
[email protected]

About Ennov

Ennov provides a comprehensive software platform to manage the most demanding processes of life sciences organizations in a compliant and efficient way. With over 20 years of experience, Ennov’s cloud-based solutions cover Regulatory Affairs, Pharmacovigilance, Quality, Clinical, and Document Management. Dedicated to innovation and excellence, Ennov’s solutions are used by more than 450 Life Science companies and 500,000 users worldwide, helping them to bring their products to market faster while maintaining compliance with regulatory requirements.

Share :

Facebook
Twitter
LinkedIn

Register for free to access to our library of exclusive content!

Highlight Post

Recent Posts